Abstract PAK3-related intellectual disability is caused by mutations in the gene encoding the p21-activated kinase (PAK) protein. It is characterized by mild to moderate cognitive impairment, micro/normocephaly, and a neurobehavioral phenotype characterized by short attention span, anxiety, restlessness, aggression, and self-abusive behaviors. The authors report a patient with a novel PAK3 mutation, who presented with intellectual disability, severe automutilation, and epilepsy. His magnetic resonance imaging changes were most likely secondary to lacerations from parenchymal contusions. His behavior was difficult to manage with behavior interventions or multiple medications. After finding low levels of dopamine and borderline low serotonin metabolites in the spinal fluid, treatment with low dose L-dopa/carbidopa and 5-hydroxytryptophan significantly improved his self-injurious behavior. This is the first case of PAK3-related intellectual disability presenting with severe self-injury with improvement following treatment. The patient's response to neurotransmitter replacement therapy raises the question if this treatment intervention might help other individuals suffering genetic syndromes and self-injurious behaviors.
(PAK) protein was described first by Allen et al in 1998. 2 Only 6 families have been reported in the literature since then, and the most consistent features in clinical presentation was mild to moderate intellectual disability, micro/normocephaly, the appearance of large ears, oral motor hypotonia (drooling), and a neurobehavioral phenotype with short attention span, anxiety, restlessness and aggression. [3] [4] [5] [6] [7] Severe self-injurious behavior, epilepsy and brain magnetic resonance imaging (MRI) changes have not been prominent features in reported families.
The authors report a male with a PAK3 missense mutation, NM_002578: c.1579A>G, resulting in a Serine to Glycine amino acid substitution NP_002569: p. (Ser527Gly), who presented with intellectual disability, self-injury resulting in moderate parenchymal changes with areas of cavitation on MRI, epilepsy, mildly low cerebrospinal fluid dopamine and borderline low serotonin metabolite. Early-onset self-injurious behavior greatly improved on neurotransmitter replacement therapy with L-dopa/carbidopa and 5-hydroxytryptophan. This mutation has not been previously reported in PAK3 associated intellectual disability, expands the phenotype and potentially offers novel therapeutic avenues, especially in cases with severe neuropsychiatric manifestations.
Case Presentation
This 17.5 year old young man was the product of an uncomplicated pregnancy, induced at 39 weeks' gestation and delivered by forceps assisted vaginal delivery. His birth weight was 4510 g (95th percentile). There was dislocation of his shoulder and a cephalhematoma. His early development was delayed in all spheres: he smiled at 7 months, sat at 8 months, crawled at 1 year, and walked at 28 months. He was putting 2 words together by age 3 years and spoke in 4-5 word sentences by age 3.5 years. He was irritable with constant crying and poor sleep from the 4th day of life and throughout infancy. At 8 months, he had low tone and when placed on his back, he would rub his head until the skin peeled off. He would rock in his crib and bang his head against the bars. At 18 months of age, he started hitting his head on hard surfaces and hit his head with his open hands up to 200 times per hour. He would hit the walls with his head to the point of punching holes. At its peak, the head banging occurred up to 4000 times daily. He has never been recognized as having sustained a concussion, but had repeated bruises on his head. On physical examination he had facial asymmetry with a long midface, full lips and a long jaw. He had a Marfanoid-like habitus, kyphosis, long fingers with cutaneous syndactyly, and calcaneovalgus deformity.
Neuropsychiatric assessment at 4 years of age revealed early deficits in reciprocal social interaction, communication, and a pattern of repetitive behaviors, consistent with a diagnosis of autism. Cognitive assessment showed that on the Bayley his nonverbal skills were in the 11-12 month range, and verbal skills at 15-19 month range. On the Vineland Scales of Adaptive Behaviour he had a standard score of 64. Impression was that of a mild intellectual disability. A speech and language assessment has been also completed and on the Rosetti scales expressive skills were at 18-24 month range, and receptive skills at the 24-27 month range. He started intensive treatment in form of applied behavioral analysis therapy, which helped with his self-injury, decreasing the daily events down from 4000 to 400. His self-injurious behavior was difficult to classify as they were atypical for autism spectrum disorder and/or obsessive-compulsive disorder. At the age of 12 years his psychiatric assessment continued to show severe self-injury with aggressive head-banging. He had a flat affect and short attention span, except when parents read him from books. A diagnosis of Cyclothymic disorder was considered.
The first seizure was a focal seizure with impaired awareness, occurred at the age of 13.5 years and was treated with phenytoin. He had further focal seizures with impaired awareness, many of which occurred in clusters. At follow-up at the age of 17.5 years, he was seizure free for 18 months on divalproex sodium, topiramate, and gabapentin. Various medications were tried for his self-injury, including quetiapine, lamotrigine, and naltrexone with no effect. He was under continuing care and supervision of a Child Psychiatrist. His symptoms worsened on trials of fluvoxamine, methylphenidate, chlorpromazine, risperidone, tetrabenazine, and sertraline.
As part of his diagnostic investigations he had a lumbar puncture for cerebrospinal fluid glucose, lactate, amino acids and biogenic amine neurotransmitters. When the low level of cerebrospinal fluid homovanillic acid (dopamine metabolite) was found, a trial of L-dopa/carbidopa 50 mg L-dopa TID and a small dose of 5-hydroxytryptophan, 25 mg TID were added to his daily medications. Following initiation, his self-injurious behavior improved significantly and almost immediately. His mother described the treatment as "life-changing."
He lives in a group home and before the neurotransmitter treatment he was often locked in a "calm down room," which has padded walls to protect him from further head injury. His caregivers used to document the daily frequency of calm down room use and the frequency of daily episodes of self-injurious behavior. This intervention decreased markedly after he started dopamine/serotonin treatment; from an average of 15-20 times/ day to 1-5 times/day ( Figures 1A, 1B ). His parents have been able to take him home daily for dinner, "sit down and cuddle in front of the TV and enjoy a whole hockey game," which they have not been able to do before for many years. Additional benefits of treatment reported by parents were the improved mood and overall mental health. He was rarely happy before. Since he has been on this treatment, his caregivers report that he is content, less anxious and generally happier. Home visits increased from 2.5 hours 4 times a week, to 4.5 hour visits 7 nights per week. The family went from finding it stressful for him to come home to enjoying their time together. This positive change has persisted on follow-up after 1 year on treatment.
Family History
He has 1 healthy sister and no brothers. His mother's family is of Finnish descent. Mother and a maternal aunt have anxiety. The maternal grandmother's side showed a predominance of females and no history of learning concerns or intellectual disability. His maternal grandfather was described as having autistic features and he developed dementia and a neurodegenerative disorder in his fifties. He also had anxiety. Examination of the brain at autopsy showed Lewy bodies and cerebral amyloid angiopathy. Grandfather's brother had schizophrenia and was institutionalized, and 2 of his sisters likely had mental illness, but no specific diagnosis was made ( Figure 2 ).
Investigations Neuroimaging
CT head scan at age 2 years and MRI of the brain at 3 years ( Figures 3A, 3B ) showed mild, nonspecific ventriculomegaly. MRI of the brain at the age of 15 years showed an increase in ventricular size, a thin corpus callosum, thin optic radiations, multifocal areas of white matter cavitation of the left occipital lobe, left temporal lobe and the right parietal and occipital lobes extending to the postcentral gyrus ( Figures 4A, 4B ). The frontal lobes were uninvolved. MR spectroscopy in normal appearing brain showed normal metabolite peaks. The imaging findings were interpreted as likely due to lacerations from parenchymal contusions.
EEG Examination
EEG examination at the age of 7 years showed background dysrhythmia and bifrontal paroxysmal slowing but no epileptiform abnormalities. EEG examination at the age of 12 years showed bilateral central parietal slowing, bilateral mid central parietal sharp waves maximal on the right side. EEG at the age of 14 years and 10 months showed background dysrhythmia, delta in the right occipital temporal area, and right hemisphere sharp waves maximal in the right posterior temporal region.
Neurometabolic Investigations
Neurometabolic investigations and testing for fragile X were negative. Further extensive biochemical and genetic investigations, according to the TIDE protocol did not yield a diagnosis. 8 Evaluation of neurotransmitter monoamine metabolites in the cerebrospinal fluid revealed a mildly decreased level of homovanillic acid (Table 1 ). 
Methods and Results
As part of the authors' TIDEX gene discovery project (UBC IRB approval H12-00067) WES was performed for the index and his unaffected parents using the Agilent SureSelect kit and Illumina HiSeq 2000 (Perkin-Elmer, USA). The sequencing reads were aligned to the human reference genome version hg19 and rare variants were identified and assessed for their potential to disrupt protein function, and subsequently screened under a series of genetic models: homozygous, hemizygous, compound heterozygous and de novo. In total, the authors identified 10 candidate genes affected by rare variants: 1 homozygous (ACAP1), 2 hemizygous (PAK3 and MAGEC1), and 7 compound heterozygous (SYNE2, FAM208B, BAZ2B, TTN, NEB, ZFHX3, and DNAH1); there were no candidate genes with de novo variants. Of these 10 candidates, a variant located on chromosome X affecting PAK3 gene (MIM 300142) was considered a functional candidate: g.110463619A>G [c.1579A>G; p.(Ser527Gly); NP_002569]. This variant is rare, observed with 0.0003 frequency in dbSNP (Build 147), 0.0001286 frequency in Exome Aggregation Consortium, and not observed in the authors' in-house genome database (comprising of more than 400 exome and genome sequencing results). The variant is predicted to be deleterious by multiple tools: high 21.8 Combined Annotation Dependent Depletion score 9 a Sorting Tolerant From Intolerant 10 prediction score of 0.001 (cutoff ¼ 0.05) and Polyphen2 11 "probably damaging score" of 1.000. Sanger sequencing confirmed the proband to be hemizygous for the PAK3 variant and mother to be heterozygous.
Participant's written informed consent was obtained.
Discussion
Intellectual disability affects about 2-3% of the population. 12 The etiology of intellectual disability is extremely heterogeneous, and in the Western world it appears that genetic conditions, including chromosomal abnormalities and monogenic syndromes are responsible for at least 40-60%. 12 WES has proven to be a powerful approach to defining the genetic basis of intellectual disability, as illustrated here. Even more important, unraveling the involved pathways may provide opportunities for therapeutic intervention. 13 In those cases in which brain structure is normal, there is growing evidence that the genetic defects underlying intellectual disability affect proteins that are enriched at the synaptic compartments, regulating synaptic activity and morphogenesis of dendritic spines. Pavlowsky et al proposed the term "synaptopathy" in 2012 and reviewed well-known signaling pathways to explain the theory of correlation between synapsis and cognitive dysfunction. 14 The most studied signaling pathways are of the small G-protein family Rho-GTPases (RhoA, Rac, Cdc42). These are key regulators of actin cytoskeleton dynamic, which induce structural plasticity of dendritic spines, change the synaptic efficacy, and result in long-term potentiation (LTP) and long-term depression. 15 Many of these Rho-GTPases have been implicated in causing intellectual disability. Their upstream and down-stream signaling pathways are well characterized. The downstream proteins include kinases, p21 protein (Cdc42/Rac)-activated kinase 3 (PAK3) among others, that are involved in dendritic spine morphology. 16 Boda et al have shown in transfected hippocampal slice cultures that PAK3 contributes to spine morphogenesis and mutations in PAK3 result in alteration of synaptic transmission and plasticity. 17 Functionally it is a kinase, activating other signaling molecules, such as Raf1 through phosphorylation of certain serine residues.
18 PAK3 knock-out mice exhibit specific abnormalities in long-lasting synaptic plasticity and have an abnormal behavioral and learning profile.
19 p21-activated serine/threonine kinases have been implicated in the pathophysiology of several neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. 20 PAK regulation is a complex process that involves homodimer and heterodimer formation. PAK3 forms heterodimers with PAK1 in brain and co- immunoprecipitation experiments with proteins expressing 2 mutations in the kinase domain (the location of the authors' patients' mutation) that cause nonsyndromic intellectual disability have shown disruption of PAK1/PAK3 complex formation. Heterodimer formation could be the link between the PAK1 and PAK3 signaling pathways. 21 On the other hand experiments in several wild-type and mutant cell lines demonstrated that down-regulation of PAK1 increases apoptotic cell death and PAK1 is inactivated by oxidative stress. The level of antiapoptotic Bcl-2 family proteins were also decreased in the mutant cell lines, suggesting that these mutations cause early apoptosis and cell death. Animal experiments by the same authors demonstrated that increased PAK1 expression in a hemi-parkinsonian rat model recovered the loss of tyrosinehydroxylase-positive neurons in the substantia nigra. These data strongly suggest that the activity of PAK1 could be related with the survival of tyrosine-hydroxylase-positive neurons and behaviors and may function as a molecular determinant in the development of Parkinson's disease. 22 In the current patient the low level of cerebrospinal fluid dopamine metabolite can be hypothesized to be caused by the above-mentioned molecular mechanisms: diminished dendritic spines, changes in the postsynaptic density, scarcity of synaptic connections, and apoptosis of tyrosine-hydroxylase-positive neurons. Dopamine receptors localized postsynaptically in dendritic spines can influence synaptic transmission and plasticity at the level of individual spines. The exact signaling cascades and dopaminergic regulation of dendritic function and physiology of a single spine is not well characterized. 23 Tyrosine hydroxylase is the rate-limiting enzyme for catecholamine synthesis and is a heavily phosphorylated protein. It is phosphorylated at several serine residues by several kinases that include PKA, PKC, CaMKII, MAPKAP-K2, ERK1, ERK2, MSK1, and PRAK, among others. It is possible that the PAK kinases have an indirect downstream effect on phosphorylation of tyrosine hydroxylase. 24 There is also a growing body of evidence implicates spiny synapses as important substrates of pathogenesis in neuropsychiatric disorders. 25 The mainstream therapy for this type of behavioral disturbances is dopamine receptor antagonists, but the patient responded well to dopamine replacement therapy. His concurrent medication, quetiapine is a second-generation antipsychotic that has affinity for D2, 5-HT2A, H1, alpha 1 and 5-HT1A receptors. Its precise mechanism of action is unknown, but its antipsychotic effects might be related to the drug's ability to reduce dopaminergic neurotransmission in the mesolimbic pathway.
Researchers recently described the role of dopamine also in the mesiohippocampus. They have shown that presynaptic D2 receptors in dopamine fibers in the temporal hippocampus tightly modulate long-term depression expression and play a major role in the regulation of hippocampal learning and memory. 26 This is also the part in the brain with highest expression of PAK3. The hippocampus has been traditionally considered the "memory area" but in more recent literature a different role has been added: a brain integrator of emotion and cognition. Animal studies provide the evidence that the hippocampus acts as an anatomical driver of gain-of-function symptoms in schizophrenia and depression. 27 Dopamine has also a role in prefrontal cortex, playing a role in normal cognitive process and neuropsychiatric pathologies. Patients with primary neurotransmitter defects, such as the biopterin disorders GTP Cyclohydrolase I (OMIM 600225) and 6-Pyruvoyl-tetrahydropterin synthase (OMIM 612719) deficiencies, also may present with neuropsychiatric, mood or behavior problems even when they are on optimal neurotransmitter replacement therapy. Some patients have been observed to have anxiety disorders, depression, behavioral outbursts, oppositional defiant, aggressive and even antisocial psychotic tendencies. (Horvath, personal communication) .
There are only 6 publications describing patients with PAK3 mutations, and their developmental and behavioral phenotype (where available) are summarized in Table 2 . Although behavioral problems of various degrees have been described in 4 other families, including aggression toward others, inattention, hyperactivity, agitation and psychosis, the clinical phenotype of the patient differs from the cases reported thus far in terms of the extremely severe nature of the auto-mutilation and neuroimaging changes. The epilepsy is likely acquired and due to the severe brain trauma and the pattern of imaging changes over time support this, however the authors cannot exclude that the epilepsy is an evolving phenotype in him related to the underlying PAK3 mutation. It is likely that over time the severe repetitive head trauma resulted in the pattern of brain injury.
More research needs to be done to delineate the multitude of interactions and complexity of molecular pathways and explain the secondary neurotransmitter deficiency and/or the response to replacement therapy. In patients with intellectual disability and treatment-resistant neuropsychiatric problems the authors suggest low threshold for cerebrospinal fluid neurotransmitter metabolite analysis, and if below the level of normal, a trial of low dose dopamine and serotonin treatment.
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